Artificial Intelligence In Diagnostics Market

Publisher Grand View Research

Published Jan 23, 2026

Length 150 Pages

SKU # GV20873260

Description

Artificial Intelligence In Diagnostics Market Summary

The global artificial intelligence in diagnostics market size was estimated at USD 1.97 billion in 2025 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 21.74% from 2026 to 2033. Market growth is driven by advancements in machine learning and deep learning, enabling faster, more accurate diagnostic solutions.

In oncology, cardiology, and neurology, among the areas, the growing demand for early disease detection has led to increased adoption of AI technologies. For instance, in February 2024, Royal Philips introduced the Philips CT 5300, an advanced AI-powered CT system designed for diagnostics, interventional procedures, and screenings. The adaptable X-ray CT system enhances diagnostic accuracy, streamlines workflows, and optimizes system availability.

Rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular disorders, etc., coupled with the increasing demand for early & accurate diagnosis, are significant factors driving market growth. The increasing incidence of cancer globally has led to a growing dependence on AI in the field of oncology. According to the NIH estimates of 2023, approximately 2.0 million individuals in the U.S. are diagnosed with cancer. Breast cancer was the most diagnosed cancer, with an estimated 297,790 cases in women and 2,800 cases in men. Similarly, according to the Centers for Disease Control and Prevention (CDC), 919,032 people died from cardiovascular disease in the U.S. in 2023, equivalent to one in every three deaths.

Such a high prevalence increases the diagnostic workload. Advancements in healthcare IT infrastructure and ongoing technological developments in cloud storage, computing, and machine learning algorithms support the integration of AI-powered systems into diagnostics to provide efficient & accurate diagnoses, allowing care providers to devise timely & appropriate treatment plans. Pathology and radiology services are witnessing a widespread adoption of AI-based algorithms. For instance, in January 2026, Alpenglow Biosciences and PathNet formed a strategic partnership to develop and commercialize 3D AI diagnostic tests for prostate and bladder cancer. The collaboration advances urologic oncology from 2D to 3D pathology in the U.S., integrating imaging, AI analytics, and workflows for enhanced accuracy.

“PathNet’s leadership in urologic oncology, digitization, AI, and strong national footprint make them an exceptional partner as we bring clinical 3D pathology to market. Together, we are building diagnostic tools that deliver insights not achievable with conventional 2D histology.”

- Dr. Nicholas Reder, CEO of Alpenglow Biosciences

In addition, several AI-powered tools are used to diagnose chronic kidney disease (CKD) & kidney function tests, and various chronic diseases. For instance, in May 2024, Premier, Inc. partnered with AstraZeneca to launch the Uncover CKD - Care Collective initiative. The aim is to identify patients with undiagnosed CKD, raise awareness among healthcare providers, and assist U.S. health systems in improving their CKD diagnosis, treatment, and management. Leveraging Premier’s PINC AI technology and services platform, the initiative seeks to address the increasing prevalence of undiagnosed CKD and its associated economic burden on the U.S. healthcare system.

Global Artificial Intelligence In Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial intelligence in diagnostics market report based on component, diagnosis type, and region:

Component Outlook (Revenue, USD Million, 2021 - 2033)
Software
Hardware
Services
Diagnosis Type Outlook (Revenue, USD Million, 2021 - 2033)
Cardiology
Oncology
Pathology
Radiology
Chest and Lung
Neurology
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Norway
Denmark
Sweden
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation and Scope; 1.1.1. Segment Definitions; 1.1.1.1. Product & Service Segment; 1.1.1.2. Application Segment; 1.1.1.3. End Use Segment; 1.2. Regional Scope; 1.3. Estimates and Forecast Timeline; 1.4. Objective; 1.4.1. Objective 1; 1.4.2. Objective2; 1.5. Research Methodology; 1.6. Information Procurement; 1.6.1. Purchased Database; 1.6.2. GVR’s Internal Database; 1.6.3. Secondary Sources; 1.6.4. Primary Research; 1.7. Information or Data Analysis:; 1.7.1. Data Analysis Models; 1.8. Market Formulation & Validation; 1.9. Model Details; 1.9.1. Commodity Flow Analysis; 1.10. List of Secondary Sources; 1.11. List of Abbreviations
Chapter 2. Executive Summary: 2.1. Market Snapshot; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent Market Outlook; 3.1.2. Related/Ancillary Market Outlook; 3.2. Market Dynamics; 3.2.1. Market Driver Analysis; 3.2.1.1. Growth of nucleic acid–based therapies; 3.2.1.2. Rising use in molecular diagnostics; 3.2.2. Market Restraint Analysis; 3.2.2.1. High cost associated with genomics research; 3.3. Industry Analysis Tools; 3.3.1. Porter’s Five Forces Analysis; 3.3.2. PESTEL Analysis
Chapter 4. Product & Service Business Analysis: 4.1. Product & Service Segment Dashboard; 4.2. Oligonucleotide Synthesis Market: Product & Service Movement Analysis; 4.3. Oligonucleotides; 4.3.1. Global oligonucleotides market, 2021 - 2033 (USD million); 4.3.2. Product type; 4.3.2.1. Global product type oligonucleotides market, 2021 - 2033 (USD million); 4.3.2.2. DNA; 4.3.2.2.1. Global DNA market, 2021 - 2033 (USD million); 4.3.2.2.2. Technology; 4.3.2.2.2.1. Global technology oligonucleotides market, 2021 - 2033 (USD million); 4.3.2.2.2.2. Column-based; 4.3.2.2.2.2.1. Global column-based market, 2021 - 2033 (USD million); 4.3.2.2.2.3. Array-based; 4.3.2.2.2.3.1. Global array-based market, 2021 - 2033 (USD million); 4.3.2.3. RNA; 4.3.2.3.1. Global RNA market, 2021 - 2033 (USD million); 4.3.2.3.2. Technology; 4.3.2.3.2.1. Global technology oligonucleotides market, 2021 - 2033 (USD million); 4.3.2.3.2.2. Column-based; 4.3.2.3.2.2.1. Global column-based market, 2021 - 2033 (USD million); 4.3.2.3.2.3. Array-based; 4.3.2.3.2.3.1. Global array-based market, 2021 - 2033 (USD million); 4.3.2.3.3. Type; 4.3.2.3.3.1. Global type oligonucleotides market, 2021 - 2033 (USD million); 4.3.2.3.3.2. Short RNA Oligos (<65 nt); 4.3.2.3.3.2.1. Global short RNA oligos (<65 nt) market, 2021 - 2033 (USD million); 4.3.2.3.3.3. Long RNA Oligos (>65 nt); 4.3.2.3.3.3.1. Global long RNA oligos (>65 nt) market, 2021 - 2033 (USD million); 4.3.2.3.3.4. CRISPR (sgRNA); 4.3.2.3.3.4.1. Global CRISPR (sgRNA) market, 2021 - 2033 (USD million); 4.4. Equipment/Synthesizer; 4.4.1. Global equipment/synthesizer market, 2021 - 2033 (USD million); 4.5. Reagents; 4.5.1. Global reagents market, 2021 - 2033 (USD million); 4.6. Services; 4.6.1. Global Services market, 2021 - 2033 (USD million); 4.6.2. DNA; 4.6.2.1. Global DNA market, 2021 - 2033 (USD million) market, 2021 - 2033 (USD million); 4.6.2.2. Custom Oligo Synthesis Services; 4.6.2.2.1. Global custom oligo synthesis services market, 2021 - 2033 (USD million); 4.6.2.2.2. 25 nmol; 4.6.2.2.2.1. Global 25 nmol market, 2021 - 2033 (USD million); 4.6.2.2.3. 50 nmol; 4.6.2.2.3.1. Global 50 nmol market, 2021 - 2033 (USD million); 4.6.2.2.4. 200 nmol; 4.6.2.2.4.1. Global 200 nmol market, 2021 - 2033 (USD million); 4.6.2.2.5. 1000 nmol; 4.6.2.2.5.1. Global 1000 nmol market, 2021 - 2033 (USD million); 4.6.2.2.6. 10000 nmol; 4.6.2.2.6.1. Global 10000 nmol market, 2021 - 2033 (USD million); 4.6.2.3. Modification Services; 4.6.2.3.1. Global modification services market, 2021 - 2033 (USD million); 4.6.2.4. Purification Services; 4.6.2.4.1. Global purification services market, 2021 - 2033 (USD million); 4.6.3. RNA; 4.6.3.1. Global RNA market, 2021 - 2033 (USD million); 4.6.3.2. Global DNA market, 2021 - 2033 (USD million) market, 2021 - 2033 (USD million); 4.6.3.3. Custom Oligo Synthesis Services; 4.6.3.3.1. Global custom oligo synthesis services market, 2021 - 2033 (USD million); 4.6.3.3.2. 25 nmol; 4.6.3.3.2.1. Global 25 nmol market, 2021 - 2033 (USD million); 4.6.3.3.3. 50 nmol; 4.6.3.3.3.1. Global 50 nmol market, 2021 - 2033 (USD million); 4.6.3.3.4. 200 nmol; 4.6.3.3.4.1. Global 200 nmol market, 2021 - 2033 (USD million); 4.6.3.3.5. 1000 nmol; 4.6.3.3.5.1. Global 1000 nmol market, 2021 - 2033 (USD million); 4.6.3.3.6. 10000 nmol; 4.6.3.3.6.1. Global 10000 nmol market, 2021 - 2033 (USD million); 4.6.3.4. Modification Services; 4.6.3.4.1. Global modification services market, 2021 - 2033 (USD million); 4.6.3.5. Purification Services; 4.6.3.5.1. Global purification services market, 2021 - 2033 (USD million)
Chapter 5. Application Business Analysis: 5.1. Application Segment Dashboard; 5.2. Oligonucleotide Synthesis Market: Application Movement Analysis; 5.3. PCR Primers; 5.3.1. Global PCR primers market, 2021 - 2033 (USD million); 5.4. PCR Assays and Panels; 5.4.1. Global PCR assays and panels market, 2021 - 2033 (USD million); 5.5. Sequencing; 5.5.1. Global sequencing market, 2021 - 2033 (USD million); 5.6. DNA Microarrays; 5.6.1. Global DNA microarrays market, 2021 - 2033 (USD million); 5.7. Fluorescence In Situ Hybridization (FISH); 5.7.1. Global Fluorescence In Situ Hybridization (FISH) market, 2021 - 2033 (USD million); 5.8. Antisense Oligonucleotides; 5.8.1. Global antisense oligonucleotides market, 2021 - 2033 (USD million); 5.9. Other Applications; 5.9.1. Global other applications market, 2021 - 2033 (USD million)
Chapter 6. End Use Business Analysis: 6.1. End Use Segment Dashboard; 6.2. Oligonucleotide Synthesis Market: End Use Movement Analysis; 6.3. Academic Research Institutes; 6.3.1. Global academic research institutes market, 2021 - 2033 (USD million); 6.4. Diagnostic Laboratories; 6.4.1. Global diagnostic laboratories market, 2021 - 2033 (USD million); 6.5. Pharmaceutical and Biotechnology Companies; 6.5.1. Global pharmaceutical and biotechnology companies market, 2021 - 2033 (USD million)
Chapter 7. Regional Business Analysis: 7.1. Oligonucleotide Synthesis Market Share By Region, 2025 & 2033; 7.2. North America; 7.2.1. North America Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.2.2. U.S.; 7.2.2.1. Key Country Dynamics; 7.2.2.2. Competitive Scenario; 7.2.2.3. Regulatory Framework; 7.2.2.4. U.S. Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.2.3. Canada; 7.2.3.1. Key Country Dynamics; 7.2.3.2. Competitive Scenario; 7.2.3.3. Regulatory Framework; 7.2.3.4. Canada Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.2.4. Mexico; 7.2.4.1. Key Country Dynamics; 7.2.4.2. Competitive Scenario; 7.2.4.3. Regulatory Framework; 7.2.4.4. Mexico Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3. Europe; 7.3.1. Europe Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.2. UK; 7.3.2.1. Key Country Dynamics; 7.3.2.2. Competitive Scenario; 7.3.2.3. Regulatory Framework; 7.3.2.4. UK Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.3. Germany; 7.3.3.1. Key Country Dynamics; 7.3.3.2. Competitive Scenario; 7.3.3.3. Regulatory Framework; 7.3.3.4. Germany Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.4. France; 7.3.4.1. Key Country Dynamics; 7.3.4.2. Competitive Scenario; 7.3.4.3. Regulatory Framework; 7.3.4.4. France Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.5. Italy; 7.3.5.1. Key Country Dynamics; 7.3.5.2. Competitive Scenario; 7.3.5.3. Regulatory Framework; 7.3.5.4. Italy Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.6. Spain; 7.3.6.1. Key Country Dynamics; 7.3.6.2. Competitive Scenario; 7.3.6.3. Regulatory Framework; 7.3.6.4. Spain Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.7. Denmark; 7.3.7.1. Key Country Dynamics; 7.3.7.2. Competitive Scenario; 7.3.7.3. Regulatory Framework; 7.3.7.4. Denmark Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.8. Sweden; 7.3.8.1. Key Country Dynamics; 7.3.8.2. Competitive Scenario; 7.3.8.3. Regulatory Framework; 7.3.8.4. Sweden Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.3.9. Norway; 7.3.9.1. Key Country Dynamics; 7.3.9.2. Competitive Scenario; 7.3.9.3. Regulatory Framework; 7.3.9.4. Norway Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4. Asia Pacific; 7.4.1. Asia Pacific Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4.2. Japan; 7.4.2.1. Key Country Dynamics; 7.4.2.2. Competitive Scenario; 7.4.2.3. Regulatory Framework; 7.4.2.4. Japan Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4.3. China; 7.4.3.1. Key Country Dynamics; 7.4.3.2. Competitive Scenario; 7.4.3.3. Regulatory Framework; 7.4.3.4. China Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4.4. India; 7.4.4.1. Key Country Dynamics; 7.4.4.2. Competitive Scenario; 7.4.4.3. Regulatory Framework; 7.4.4.4. India Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4.5. Australia; 7.4.5.1. Key Country Dynamics; 7.4.5.2. Competitive Scenario; 7.4.5.3. Regulatory Framework; 7.4.5.4. Australia Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4.6. Thailand; 7.4.6.1. Key Country Dynamics; 7.4.6.2. Competitive Scenario; 7.4.6.3. Regulatory Framework; 7.4.6.4. Thailand Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.4.7. South Korea; 7.4.7.1. Key Country Dynamics; 7.4.7.2. Competitive Scenario; 7.4.7.3. Regulatory Framework; 7.4.7.4. South Korea Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.5. Latin America; 7.5.1. Latin America Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.5.2. Brazil; 7.5.2.1. Key Country Dynamics; 7.5.2.2. Competitive Scenario; 7.5.2.3. Regulatory Framework; 7.5.2.4. Brazil Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.5.3. Argentina; 7.5.3.1. Key Country Dynamics; 7.5.3.2. Competitive Scenario; 7.5.3.3. Regulatory Framework; 7.5.3.4. Argentina Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.6. MEA; 7.6.1. MEA Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.6.2. South Africa; 7.6.2.1. Key Country Dynamics; 7.6.2.2. Competitive Scenario; 7.6.2.3. Regulatory Framework; 7.6.2.4. South Africa Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.6.3. Saudi Arabia; 7.6.3.1. Key Country Dynamics; 7.6.3.2. Competitive Scenario; 7.6.3.3. Regulatory Framework; 7.6.3.4. Saudi Arabia Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.6.4. UAE; 7.6.4.1. Key Country Dynamics; 7.6.4.2. Competitive Scenario; 7.6.4.3. Regulatory Framework; 7.6.4.4. UAE Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million); 7.6.5. Kuwait; 7.6.5.1. Key Country Dynamics; 7.6.5.2. Competitive Scenario; 7.6.5.3. Regulatory Framework; 7.6.5.4. Kuwait Oligonucleotide Synthesis Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Company Categorization; 8.2. Strategy Mapping; 8.3. Company Market Share Analysis, 2025; 8.4. Company Profiles/Listing; 8.4.1. Thermo Fisher Scientific Inc.; 8.4.1.1. Overview; 8.4.1.2. Financial Performance; 8.4.1.3. Product Benchmarking; 8.4.1.4. Strategic Initiatives; 8.4.2. Merck KGaA; 8.4.2.1. Overview; 8.4.2.2. Financial Performance; 8.4.2.3. Product Benchmarking; 8.4.2.4. Strategic Initiatives; 8.4.3. Danaher; 8.4.3.1. Overview; 8.4.3.2. Financial Performance; 8.4.3.3. Product Benchmarking; 8.4.3.4. Strategic Initiatives; 8.4.4. Revvity Discovery Limited; 8.4.4.1. Overview; 8.4.4.2. Financial Performance; 8.4.4.3. Product Benchmarking; 8.4.4.4. Strategic Initiatives; 8.4.5. Agilent Technologies, Inc.; 8.4.5.1. Overview; 8.4.5.2. Financial Performance; 8.4.5.3. Product Benchmarking; 8.4.5.4. Strategic Initiatives; 8.4.6. Bio-Synthesis, Inc.; 8.4.6.1. Overview; 8.4.6.2. Product Benchmarking; 8.4.6.3. Strategic Initiatives; 8.4.7. Kaneka Eurogentec S.A.; 8.4.7.1. Overview; 8.4.7.2. Product Benchmarking; 8.4.7.3. Strategic Initiatives; 8.4.8. LGC Biosearch Technologies; 8.4.8.1. Overview; 8.4.8.2. Financial Performance; 8.4.8.3. Product Benchmarking; 8.4.8.4. Strategic Initiatives; 8.4.9. Biolegio; 8.4.9.1. Overview; 8.4.9.2. Product Benchmarking; 8.4.9.3. Strategic Initiatives; 8.4.10. Twist Bioscience; 8.4.10.1. Overview; 8.4.10.2. Financial Performance; 8.4.10.3. Product Benchmarking; 8.4.10.4. Strategic Initiatives

Pricing

Currency Rates

Single User Email from Publisher $5,950
Multi User License Fulfilled by Publisher $6,950
Global Site License Email from Publisher $8,950

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now